{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:55:28Z","timestamp":1781708128701,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.07.049","type":"journal-article","created":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T16:17:03Z","timestamp":1596989823000},"page":"6205-6214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349\u00a0year old patients"],"prefix":"10.1016","volume":"38","author":[{"given":"\u00c9tienne","family":"Racine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Gilca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-2592","authenticated-orcid":false,"given":"Shainoor","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-1658","authenticated-orcid":false,"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.07.049_b0005","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/infdis\/jiy403","article-title":"Immunobiology of Varicella-Zoster Virus Infection","volume":"218","author":"Laing","year":"2018","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.07.049_b0010","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"issue":"3 Suppl","key":"10.1016\/j.vaccine.2020.07.049_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/erv.10.32","article-title":"Vaccination: a new option to reduce the burden of herpes zoster","volume":"9","author":"Mick","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.07.049_b0020","doi-asserted-by":"crossref","unstructured":"Weinberg JM. Herpes zoster: Epidemiology, natural history, and common complications. J Am Acad Dermatol, 2007; 57(6, Supplement):S130\u20115.","DOI":"10.1016\/j.jaad.2007.08.046"},{"issue":"1","key":"10.1016\/j.vaccine.2020.07.049_b0025","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","article-title":"What does epidemiology tell us about risk factors for herpes zoster?","volume":"4","author":"Thomas","year":"2004","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2020.07.049_b0030","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","article-title":"Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysis","volume":"92","author":"Kawai","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2020.07.049_b0035","doi-asserted-by":"crossref","unstructured":"Buchan SA, Daneman N, Wang J, Garber G, Wormsbecker AE, Wilson SE, et al. Incidence of Hospitalizations and Emergency Department Visits for Herpes Zoster in Immunocompromised and Immunocompetent Adults in Ontario, Canada, 2002\u20132016. Clin Infect Dis, 2019 Aug 22. pii: ciz769. http:\/\/doi.org\/10.1093\/cid\/ciz769. [Epub ahead of print].","DOI":"10.1093\/cid\/ciz769"},{"key":"10.1016\/j.vaccine.2020.07.049_b0040","unstructured":"Merck Canada Inc. ZOSTAVAX\u00ae II (zoster vaccine live, attenuated [Oka\/Merck], refrigerator-stable): Merck Canada Inc.; 2018: 29 p. Available at: https:\/\/www.merck.ca\/static\/pdf\/ZOSTAVAX_II-PM_E.pdf. Accessed 10 January 2020."},{"issue":"12","key":"10.1016\/j.vaccine.2020.07.049_b0045","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/14760584.2017.1395703","article-title":"Studies with herpes zoster vaccines in immune compromised patients","volume":"16","author":"Levin","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.07.049_b0050","unstructured":"GlaxoSmithKline Inc. SHINGRIX Herpes Zoster vaccine (non-live recombinant, AS01B adjuvanted). GlaxoSmithKline Inc.; 2019: 30 p. Available at: https:\/\/ca.gsk.com\/media\/1350788\/shingrix_pm-2017-10-13.pdf. Accessed 10 January 2020."},{"key":"10.1016\/j.vaccine.2020.07.049_b0055","unstructured":"Government of Canada. Updated Recommendations on the Use of Herpes Zoster Vaccines. Available at\u00a0: https:\/\/www.canada.ca\/en\/services\/health\/publications\/healthy-living\/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed 10 January 2020."},{"key":"10.1016\/j.vaccine.2020.07.049_b0060","unstructured":"Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. Available at: https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6703a5.htm. Accessed 10 January 2020."},{"key":"10.1016\/j.vaccine.2020.07.049_b0065","unstructured":"Prisma. Transparent reporting of systematic reviews and meta-analyses, Available at: http:\/\/prisma-statement.org\/. Accessed 10 January 2020."},{"key":"10.1016\/j.vaccine.2020.07.049_b0070","unstructured":"Evidence Partners: Available at: https:\/\/v2dis-prod.evidencepartners.com\/Login\/Login.phpl. Accessed 10 January 2020."},{"key":"10.1016\/j.vaccine.2020.07.049_b0075","unstructured":"Government of Canada. ARCHIVED - Canada Communicable Disease Report: Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/reports-publications\/canada-communicable-disease-report-ccdr\/monthly-issue\/2009-35\/methods-national-advisory-committee-immunization.html. Accessed 10 January 2020."},{"issue":"19","key":"10.1016\/j.vaccine.2020.07.049_b0080","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vaccine.2020.07.049_b0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis, Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2020.07.049_b0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.07.049_b0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2020.07.049_b0100","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.07.049_b0105","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4161\/hv.24269","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ\/su): a phase-I, open-label study in Japanese adults","volume":"9","author":"Lal","year":"2013","journal-title":"Hum Vaccines Immunother"},{"issue":"18","key":"10.1016\/j.vaccine.2020.07.049_b0110","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.vaccine.2019.03.043","article-title":"Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials","volume":"37","author":"L\u00f3pez-Fauqued","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.07.049_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2017.1329012","article-title":"Vaccine profile of herpes zoster (HZ\/su) subunit vaccine","volume":"16","author":"Cunningham","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.07.049_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.exphem.2019.10.004","article-title":"Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies","volume":"79","author":"Scialdone","year":"2019","journal-title":"Exp Hematol"},{"issue":"14","key":"10.1016\/j.vaccine.2020.07.049_b0125","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies","volume":"35","author":"Parrino","year":"2017","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2020.07.049_b0130","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.07.049_b0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.049_b0140","doi-asserted-by":"crossref","unstructured":"Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, et al. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ\/su. Vaccine, 2017;35(48 Pt B):6700\u20116.","DOI":"10.1016\/j.vaccine.2017.10.017"},{"issue":"11","key":"10.1016\/j.vaccine.2020.07.049_b0145","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2020.07.049_b0150","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2020.07.049_b0155","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial","volume":"125","author":"Vink","year":"2019","journal-title":"Cancer"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:50Z","timestamp":1759401950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20309804"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349\u00a0year old patients","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}